Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

Market Cap	10.98B +6.4%
Revenue (ttm)	10.31B +0.6%
Net Income	702.17M +28.4%
EPS	0.60 +25.0%
Shares Out	1.16B
PE Ratio	15.89
Forward PE	20.84
Dividend	0.21 (2.20%)
Ex-Dividend Date	n/a

Volume	13,054,836
Open	9.55
Previous Close	9.55
Day's Range	9.39 - 9.60
52-Week Range	9.07 - 13.06
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHA:600267

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approximately 70 countries worldwide. Zhejiang Hisun Pharmaceutical Co., Ltd....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1956
• Employees: 8,751
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600267

Financial Performance

In 2025, SHA:600267's revenue was 10.55 billion, an increase of 2.03% compared to the previous year's 10.34 billion. Earnings were 540.71 million, a decrease of -10.06%.